China has approved the first ingredient under its new Cosmetic Supervision and Administration Regulation (CSAR) regime, Beiersdorf’s Thiamidol 630 (Isobutylamido Thiazolyl Resorcinol).
The anti-acne treatment marks the first ingredient to be registered by the National Medical Products Administration (NMPA) since implementing CSAR in 2021.
The regulatory approval of Thiamidol 630 in China is the first step towards the complete registration of the finished goods to be distributed in domestic China.
Beiersdorf will cooperate with the NMPA to support a compliant and fast registration process to introduce the products into the Chinese market which is expected within 12 to 18 months.
Dr. Gitta Neufang, chief R&D Officer of Beiersdorf added: “Thiamidol 630 is only the second anti-spot ingredient to receive such approval in China and the first since the implementation of the CSAR.
“For our team this is another significant step in our strategy to further expand Thiamidol across our brand portfolio to address hyperpigmentation and thus touch people‘s lives.”
Beiersdorf says the patented anti-spot ingredient is the most effective against hyperpigmentation on the market.
Thiamidol 630’s efficacy has been proven in more than 110 clinical studies involving approximately 8,500 participants of all skin types.
After ten years of research and testing 50,000 compounds by Beiersdorf scientists, it was first launched in 2018 and has been rolled out across the world from 2019.
Vincent Warnery, CEO of Beiersdorf: “We are delighted about the approval of our hero ingredient Thiamidol 630 in China and would like to thank the NMPA and the National Institutes for Food and Drug Control (NIFDC) for their supervision and support in the process.”
